Helen Louise Collins
CIK 1701247 · CHIEF MEDICAL OFFICER · last filed 2026-07-21
Helen Louise Collins is a CHIEF MEDICAL OFFICER who has filed 54 SEC Form 4 insider transactions across 6 companies since 2017. The most recent filing, for ELVN, was dated Jul 21, 2026. Across all open-market trades the lifetime net is −$5.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.73M
6
54
-$5.37M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELVN | CHIEF MEDICAL OFFICER | 25,063 | $53.76 | $1.35M | -$263.4K | 1 | 2026-07-21 |
| IMRA | CHIEF MEDICAL OFFICER | 26,133 | $14.49 | $378.7K | -$5.11M | 14 | 2026-06-22 |
| KURA | Director | — | $9.31 | — | $0 | 6 | 2026-06-04 |
| IO Biotech, Inc. (IOBT) Delisted | Director | — | $0.05 | — | $0 | 3 | 2025-06-06 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | EVP and Chief Medical Officer | 69,547 | $38.00 | $2.64M | $0 | 9 | 2021-04-19 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | EVP and Chief Medical Officer | 44,298 | $178.75 | $7.92M | $0 | 14 | 2019-09-04 |
Recent Filings
54 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-21 | ELVN | Mixed | — | -$251.0K | EDGAR |
| 2026-07-17 | ELVN | Notice (144) | −15,000 | -$762.9K | EDGAR |
| 2026-06-22 | IMRA | Mixed | — | -$206.6K | EDGAR |
| 2026-06-04 | KURA | Grant (A) | — | $0 | EDGAR |
| 2026-05-20 | IMRA | Mixed | — | -$186.6K | EDGAR |
| 2026-05-18 | ELVN | Notice (144) | −15,000 | -$620.1K | EDGAR |
| 2026-04-21 | IMRA | Mixed | — | -$226.0K | EDGAR |
| 2026-03-27 | IMRA | Mixed | — | -$1.30M | EDGAR |
| 2026-03-25 | ELVN | Notice (144) | −45,000 | -$1.40M | EDGAR |
| 2026-03-19 | IMRA | Mixed | — | -$126.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.